Q-omics provides the consensus-scored NUS1 profile across patient tissues and cancer cell-line models. NUS1 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, NUS1 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, NUS1 RNA expression shows 19,853 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, THCA, and ACC as cancer lineages where NUS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUS1 survival associations across molecular data types. NUS1 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUS1 RNA expression–survival associations across cancer types. High NUS1 expression shows unfavorable associations in CESC, KIRP, LIHC, ACC, HNSC and LUSC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for NUS1 RNA expression.
This table summarizes NUS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for NUS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUS1 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, STAD, BLCA and ESCA. The THCA box plot shows higher NUS1 RNA expression in normal versus tumor tissue (log2 FC = −1.111, t-test p < 0.001).
This table shows molecular features associated with NUS1 in patient tissues and cancer cell lines. In patient samples, NUS1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NUS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
